Tag: patent litigation

30-Month Stay: How Litigation Delays Generic Drug Approval

The 30-month stay under the Hatch-Waxman Act delays generic drug approvals by tying FDA approval to patent litigation. This mechanism, meant to balance innovation and access, often extends brand monopolies, raising drug costs by billions annually.